SG Americas Securities’s Palvella Therapeutics PVLA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$308K Sell
2,472
-217
-8% -$22.6K ﹤0.01% 2446
2025
Q4
$281K Buy
+2,689
New +$229K ﹤0.01% 2785
2022
Q1
Sell
-230
Closed -$70K 3529
2021
Q4
$70K Buy
+230
New +$73.7K ﹤0.01% 3155
2020
Q3
Sell
-337
Closed -$84K 3554
2020
Q2
$84K Buy
337
+129
+62% +$30.2K ﹤0.01% 3433
2020
Q1
$38K Buy
+208
New +$52.4K ﹤0.01% 3219
2019
Q1
Sell
-170
Closed -$36K 3678
2018
Q4
$36K Buy
+170
New +$52.7K ﹤0.01% 2868

Other funds holding PVLA

SG Americas Securities's PVLA Position: Q1 2026 in Review

SG Americas Securities reduced its Palvella Therapeutics (PVLA) stake by 8.1% in Q1 2026, selling an estimated $22.6K and leaving 2,472 shares worth $308K. The position accounts for ﹤0.01% of the portfolio, ranked #2446.

SG Americas Securities first reported a position in PVLA in Q4 2018 and has held it in 6 quarters since. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

  • SG Americas Securities held 2,472 shares of Palvella Therapeutics worth $308K as of Q1 2026.
  • SG Americas Securities sold 217 Palvella Therapeutics shares in Q1 2026, an estimated $22.6K.
  • Palvella Therapeutics made up ﹤0.01% of SG Americas Securities's portfolio in Q1 2026, its #2446 holding.
  • SG Americas Securities first reported a position in Palvella Therapeutics in Q4 2018 and has held it in 6 quarters since.
  • 180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.